Cross - validation | Src inhibitors | Src non-inhibitors | Q | C | ||||||
---|---|---|---|---|---|---|---|---|---|---|
No of training/ testing inhibitors | TP | FN | SE | No of training/testing non-inhibitors | TN | FP | SP | |||
1 | 1362/341 | 319 | 22 | 93.55% | 50654/12664 | 12413 | 251 | 98.02% | 97.90% | 0.715 |
2 | 1362/341 | 324 | 17 | 95.01% | 50654/12664 | 12380 | 284 | 97.76% | 97.69% | 0.702 |
3 | 1362/341 | 330 | 11 | 96.77% | 50654/12664 | 12395 | 269 | 97.88% | 97.85% | 0.722 |
4 | 1363/340 | 330 | 10 | 97.06% | 50655/12663 | 12389 | 274 | 97.84% | 97.82% | 0.720 |
5 | 1363/340 | 318 | 22 | 93.53% | 50655/12663 | 12413 | 250 | 98.03% | 97.91% | 0.715 |
Average | Â | Â | Â | 95.19% | Â | Â | Â | 97.90% | 97.83% | 0.715 |
SD | Â | Â | Â | 0.0169 | Â | Â | Â | 0.0012 | 0.0009 | 0.0075 |
SE | Â | Â | Â | 0.0076 | Â | Â | Â | 0.0005 | 0.0004 | 0.0034 |